290 related articles for article (PubMed ID: 28681803)
41. Safety and immunogenicity of 26-valent group a streptococcus vaccine in healthy adult volunteers.
McNeil SA; Halperin SA; Langley JM; Smith B; Warren A; Sharratt GP; Baxendale DM; Reddish MA; Hu MC; Stroop SD; Linden J; Fries LF; Vink PE; Dale JB
Clin Infect Dis; 2005 Oct; 41(8):1114-22. PubMed ID: 16163629
[TBL] [Abstract][Full Text] [Related]
42. Lipid core peptide technology and group A streptococcal vaccine delivery.
Olive C; Batzloff MR; Toth I
Expert Rev Vaccines; 2004 Feb; 3(1):43-58. PubMed ID: 14761243
[TBL] [Abstract][Full Text] [Related]
43. Decoding the molecular epidemiology of group A streptococcus - an Indian perspective.
Abraham T; Sistla S
J Med Microbiol; 2019 Jul; 68(7):1059-1071. PubMed ID: 31192782
[TBL] [Abstract][Full Text] [Related]
44. M-Protein Analysis of Streptococcus pyogenes Isolates Associated with Acute Rheumatic Fever in New Zealand.
Williamson DA; Smeesters PR; Steer AC; Steemson JD; Ng AC; Proft T; Fraser JD; Baker MG; Morgan J; Carter PE; Moreland NJ
J Clin Microbiol; 2015 Nov; 53(11):3618-20. PubMed ID: 26292296
[TBL] [Abstract][Full Text] [Related]
45. Cutting edge issues in rheumatic fever.
Chang C
Clin Rev Allergy Immunol; 2012 Apr; 42(2):213-37. PubMed ID: 21597903
[TBL] [Abstract][Full Text] [Related]
46. Protection against group A streptococcal infection by vaccination with self-adjuvanting lipid core M protein peptides.
Olive C; Hsien K; Horváth A; Clair T; Yarwood P; Toth I; Good MF
Vaccine; 2005 Mar; 23(17-18):2298-303. PubMed ID: 15755615
[TBL] [Abstract][Full Text] [Related]
47. Similar ability of FbaA with M protein to elicit protective immunity against group A streptococcus challenge in mice.
Ma CQ; Li CH; Wang XR; Zeng RH; Yin XL; Feng HD; Wei L
Cell Mol Immunol; 2009 Feb; 6(1):73-7. PubMed ID: 19254483
[TBL] [Abstract][Full Text] [Related]
48. Clinical development strategy for a candidate group A streptococcal vaccine.
Schödel F; Moreland NJ; Wittes JT; Mulholland K; Frazer I; Steer AC; Fraser JD; Carapetis J
Vaccine; 2017 Apr; 35(16):2007-2014. PubMed ID: 28318768
[TBL] [Abstract][Full Text] [Related]
49. Current status of group A streptococcal vaccine development.
Dale JB
Adv Exp Med Biol; 2008; 609():53-63. PubMed ID: 18193657
[TBL] [Abstract][Full Text] [Related]
50. Atlas of group A streptococcal vaccine candidates compiled using large-scale comparative genomics.
Davies MR; McIntyre L; Mutreja A; Lacey JA; Lees JA; Towers RJ; Duchêne S; Smeesters PR; Frost HR; Price DJ; Holden MTG; David S; Giffard PM; Worthing KA; Seale AC; Berkley JA; Harris SR; Rivera-Hernandez T; Berking O; Cork AJ; Torres RSLA; Lithgow T; Strugnell RA; Bergmann R; Nitsche-Schmitz P; Chhatwal GS; Bentley SD; Fraser JD; Moreland NJ; Carapetis JR; Steer AC; Parkhill J; Saul A; Williamson DA; Currie BJ; Tong SYC; Dougan G; Walker MJ
Nat Genet; 2019 Jun; 51(6):1035-1043. PubMed ID: 31133745
[TBL] [Abstract][Full Text] [Related]
51. Diversity of emm sequence types in group A beta-haemolytic streptococci in two remote Northern Territory Indigenous communities: implications for vaccine development.
Richardson LJ; Towers RJ; Cheng AC; Currie BJ; Carapetis JR; Giffard PM; McDonald MI
Vaccine; 2010 Jul; 28(32):5301-5. PubMed ID: 20665975
[TBL] [Abstract][Full Text] [Related]
52. Status of research and development of vaccines for Streptococcus pyogenes.
Steer AC; Carapetis JR; Dale JB; Fraser JD; Good MF; Guilherme L; Moreland NJ; Mulholland EK; Schodel F; Smeesters PR
Vaccine; 2016 Jun; 34(26):2953-2958. PubMed ID: 27032515
[TBL] [Abstract][Full Text] [Related]
53. New 30-valent M protein-based vaccine evokes cross-opsonic antibodies against non-vaccine serotypes of group A streptococci.
Dale JB; Penfound TA; Chiang EY; Walton WJ
Vaccine; 2011 Oct; 29(46):8175-8. PubMed ID: 21920403
[TBL] [Abstract][Full Text] [Related]
54. Enhancing Vaccine Efficacy by Engineering a Complex Synthetic Peptide To Become a Super Immunogen.
Nordström T; Pandey M; Calcutt A; Powell J; Phillips ZN; Yeung G; Giddam AK; Shi Y; Haselhorst T; von Itzstein M; Batzloff MR; Good MF
J Immunol; 2017 Oct; 199(8):2794-2802. PubMed ID: 28904125
[TBL] [Abstract][Full Text] [Related]
55. Vaccine Approaches To Protect against Group A Streptococcal Pharyngitis.
Fischetti VA
Microbiol Spectr; 2019 May; 7(3):. PubMed ID: 31111819
[TBL] [Abstract][Full Text] [Related]
56. Combinatorial Synthetic Peptide Vaccine Strategy Protects against Hypervirulent CovR/S Mutant Streptococci.
Pandey M; Mortensen R; Calcutt A; Powell J; Batzloff MR; Dietrich J; Good MF
J Immunol; 2016 Apr; 196(8):3364-74. PubMed ID: 26969753
[TBL] [Abstract][Full Text] [Related]
57. Intranasal administration is an effective mucosal vaccine delivery route for self-adjuvanting lipid core peptides targeting the group A streptococcal M protein.
Olive C; Sun HK; Ho MF; Dyer J; Horváth A; Toth I; Good MF
J Infect Dis; 2006 Aug; 194(3):316-24. PubMed ID: 16826479
[TBL] [Abstract][Full Text] [Related]
58. Antibody levels to the class I and II epitopes of the M protein and myosin are related to group A streptococcal exposure in endemic populations.
Brandt ER; Yarwood PJ; McMillan DJ; Vohra H; Currie B; Mammo L; Pruksakorn S; Saour J; Good MF
Int Immunol; 2001 Oct; 13(10):1335-43. PubMed ID: 11581178
[TBL] [Abstract][Full Text] [Related]
59. Prospective surveillance of streptococcal sore throat in a tropical country.
Steer AC; Jenney AW; Kado J; Good MF; Batzloff M; Magor G; Ritika R; Mulholland KE; Carapetis JR
Pediatr Infect Dis J; 2009 Jun; 28(6):477-82. PubMed ID: 19483515
[TBL] [Abstract][Full Text] [Related]
60. Group A streptococcal vaccines: paving a path for accelerated development.
Dale JB; Fischetti VA; Carapetis JR; Steer AC; Sow S; Kumar R; Mayosi BM; Rubin FA; Mulholland K; Hombach JM; Schödel F; Henao-Restrepo AM
Vaccine; 2013 Apr; 31 Suppl 2():B216-22. PubMed ID: 23598485
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
